Ube Corporation · TSE:4208
Ube — FY2015 Earnings Presentation
30 slides from Ube's earnings presentation, May 11, 2016
Slide 1: FY2015 Consolidated Results, FY2016 Consolidated Forecasts
1 FY2015 Consolidated Results FY2016 Consolidated Forecasts May 11, 2016
Slide 2: Contents
2 Contents ・ FY2015 Consolidated Results ・ FY2016 Consolidated Forecasts ・ Appendix
Slide 3: FY2015 Consolidated Results
3 FY2015 Consolidated Results
Slide 4: Scope of Consolidation
4 Scope of Consolidation － FY2015 Consolidated Results － End of FY2014 End of FY2015 Change Item Notes (A) (B) （B) - （A) + Sanshin Tsusho Co., Ltd. － Advanced Electrolyte Number of Technologies (USA) LLC consolidated 71 68 -3 － Advanced Electrolyte subsidiaries Technologies (Europe) S.L. ー UBE CHEMI
Slide 5: Material Price
5 Environmental Factors － FY2015 Consolidated Results － FY2014 FY2015 Change Item (A) (B) (B) - (A) Exchange Rate Yen/$ 109.9 120.1 10.2 (CIF) $/ｔ 820 484 -336 Naphtha (Domestic) Yen/KL 63,400 42,600 -20,800 Material Price Benzene(ACP) $/ｔ 1,090 667 -423 Benzene(USCP) $/ｔ 1,161 694 -467 Australian C
Slide 6: Major P/L & B/S Items
6 Major P/L & B/S Items － FY2015 Consolidated Results － (Billion Yen) FY2014 FY2015 Change Item (A) (B) (B) - (A) Sales 641.7 641.7 -0.0 Operating income 24.1 41.4 17.2 Ordinary income 23.2 39.6 16.3 Net income 14.6 19.1 4.4 End of FY2014 End of FY2015 Change Item (A) (B) (B) - (A) Total assets 711.
Slide 7: Sales by Segment
7 Sales by Segment － FY2015 Consolidated Results － （Billion Yen） FY2014 FY2015 Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain -15.3, Synthetic rubber -2.8, Chemicals 280.1 266.7 -13.4 Battery Materials and Fine Chemicals 5.4, Polyimide and Specialty Products -0.1, etc Pharmac
Slide 8: Operating Income by Segment
8 Operating Income by Segment － FY2015 Consolidated Results － （Billion Yen） FY2014 FY2015 Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain 9.0, Synthetic rubber -0.3, Chemicals -0.9 12.0 13.0 Battery Materials and Fine Chemicals 1.2, Polyimide and Specialty Products 1.7, etc Ph
Slide 9: Analysis of Operating Income
9 Analysis of Operating Income － FY2015 Consolidated Results － （Billion Yen） Operating Income Segment Change FY2014 FY2015 Sales Fixed Price Others (A) (B) (B) - (A) *1 Volume Cost *2 Chemicals -0.9 12.0 13.0 7.5 4.4 0.0 1.1 Pharmaceutical 0.9 1.1 0.2 0.1 -0.5 -0.0 0.7 Cement & construction Material
Slide 10: Non Operating Items
10 Non Operating Items － FY2015 Consolidated Results － （Billion Yen） FY2014 FY2015 Change Item (A) (B) (B) - (A) Operating income 24.1 41.4 17.2 Net interest expense -1.4 -1.1 0.2 Non operating income Equity in earnings of unconsolidated subsidiaries 1.5 2.9 1.4 and affiliated companies Foreign curr
Slide 11: Extraordinary Items
11 Extraordinary Items － FY2015 Consolidated Results － （Billion Yen） FY2014 FY2015 Change Item (A) (B) (B) - (A) Gain on insurance adjustment 3.8 - -3.8 Reversal of accured expenses from business withdrawal - 1.5 1.5 Loss on disposal of non-current ＊1 assets -2.7 -5.3 -2.5 Impairment Loss -1.5 -9.0
Slide 12: Operating Income – Net Income
12 Operating Income – Net Income － FY2015 Consolidated Results － （Billion Yen） FY2014 FY2015 Change Item (A) (B) (B) - (A) Operating income 24.1 41.4 17.2 Non operating item -0.9 -1.7 -0.8 Ordinary income 23.2 39.6 16.3 Extraordinary item -4.7 -11.9 -7.2 Income before income tax and minority interes
Slide 13: Consolidated Balance Sheet
13 Consolidated Balance Sheet － FY2015 Consolidated Results － （Billion Yen） End of FY2014 End of FY2015 Change Item (A) (B) (B) - (A) Current assets 282.8 276.9 -5.8 Fixed assets 428.5 402.7 -25.8 Total assets 711.5 679.7 -31.7 Interest-bearing debts 239.7 216.6 -23.0 Other liabilities 182.2 173.4 -
Slide 14: Consolidated Statements of Cash Flows
14 Consolidated Statements of Cash Flows － FY2015 Consolidated Results － （Billion Yen） Item FY2014 FY2015 Losses before income tax and minority interests 27.6, A.Cash flows from operating activities 62.1 68.6 Depreciation and amortization 35.5, Working capital -2.0, etc. B.Cash flows from investing
Slide 15: FY2016 Consolidated Forecasts
15 FY2016 Consolidated Forecasts
Slide 16: Scope of Consolidation – FY2016 Forecasts
16 Scope of Consolidation － FY2016 Consolidated Forecasts － End of End of Change Item FY2015 FY2016 Notes (A) (B) （B) - （A) Number of consolidated 68 68 ー subsidiaries Number of equity method 25 25 ー affiliates Total 93 93 ー
Slide 17: Material Price – FY2016 Forecasts
17 Environmental Factors － FY2016 Consolidated Forecasts － FY2015 FY2016 Change Item (A) (B) (B) - (A) Exchange Rate Yen/$ 120.1 110.0 -10.1 (CIF) $/ｔ 484 430 -54 Naphtha (Domestic) Yen/KL 42,600 34,900 -7,700 Material Price Benzene(ACP) $/ｔ 667 650 -17 Benzene(USCP) $/ｔ 694 700 6 Australian $/ｔ 73.
Slide 18: Major P/L & B/S Items – FY2016 Forecasts
18 Major P/L & B/S Items － FY2016 Consolidated Forecasts － （Billion Yen） FY2015 FY2016 Change Item (A) (B) (B) - (A) Sales 641.7 655.0 13.3 Operating income 41.4 35.0 -6.4 Ordinary income 39.6 33.0 -6.6 Profit attributable to owners of parent 19.1 20.0 0.9 End of FY2015 End of FY2016 Change Item (A)
Slide 19: Sales by Segment – FY2016 Forecasts
19 Sales by Segment － FY2016 Consolidated Forecasts － （Billion Yen） FY2015 FY2016 Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain -3.3, Synthetic rubber 2.5, Chemicals 266.7 278.0 11.3 Battery Materials and Fine Chemicals 9.0, Polyimide and Specialty Products 3.1, etc Pharmace
Slide 20: Operating Income by Segment – FY2016 Forecasts
20 Operating Income by Segment － FY2016 Consolidated Forecasts － （Billion Yen） FY2015 FY2016 Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain -5.3, Synthetic rubber -0.8, Chemicals 120.0 9.0 -3.0 Battery Materials and Fine Chemicals 1.1, Polyimide and Specialty Products 0.7, et
Slide 21: Analysis of Operating Income – FY2016 Forecasts
21 Analysis of Operating Income － FY2016 Consolidated Forecasts － （Billion Yen） Operating Income Segment Change FY2015 FY2016 Sales Fixed Price Others (A) (B) (B) - (A) *1 Volume Cost *2 Chemicals 12.0 9.0 -3.0 -6.6 5.4 -6.1 4.3 Pharmaceutical 1.1 1.0 -0.1 -0.3 0.6 -0.4 0.0 Cement & Construction Mat
Slide 22: Operating Income – Net Income – FY2016 Forecasts
22 Operating Income – Net Income － FY2016 Consolidated Forecasts － （Billion Yen） FY2015 FY2016 Change Item (A) (B) (B) - (A) Operating income 41.4 35.0 -6.4 Non operating item -1.7 -2.0 -0.3 Ordinary income 39.6 33.0 -6.6 Extraordinary item -11.9 -4.0 7.9 Income before income tax and minority intere
Slide 23: Appendix
23 Appendix
Slide 24: Reference: FY2015 Changes in Results - Sales by Segments
24 【Reference】 FY2015 Changes in Results - Sales by Segments - (Billion Yen) FY2015 Segment 1Q 2Q 3Q 4Q Total Chemicals 70.0 66.9 66.2 63.5 266.7 Pharmaceutical 1.7 1.4 2.4 3.5 9.2 Cement & 58.9 59.3 61.6 57.4 237.3 Construction Materials Machinery & MetalProducts 14.3 19.7 17.6 21.6 73.4 Energy & E
Slide 25: Reference: FY2015 Changes in Results - Operating Income by Segments
25 【Reference】 FY2015 Changes in Results - Operating Income by Segments - (Billion Yen) FY2015 Segment 1Q 2Q 3Q 4Q Total Chemicals 3.5 2.8 3.1 2.5 12.0 Pharmaceutical -0.0 0.2 0.3 0.5 1.1 Cement & 4.2 5.5 5.9 4.0 19.8 Construction Materials Machinery & MetalProducts 0.6 1.1 0.7 2.0 4.6 Energy & Envi
Slide 26: Reference: FY2016 Forecast - Sales / Operating Income in Half Years
26 【Reference】 FY2016 Consolidated Forecast - Sales / Operating Income in Half Years - （Billion Yen） Sales Operating income Segment First half Second half Total First half Second half Total Chemicals 133.0 145.0 278.0 -1.0 10.0 9.0 Pharmaceutical 4.5 5.5 10.0 0.5 0.5 1.0 Cement & Construction Materi
Slide 27: Major Data - Financial Results for FY2015
27 Major Data - Financial Results for FY2015 - (Billion Yen) FY2016 Item FY2014 FY2015 Forecast capital investment 42.5 34.4 48.0 Depreciation andamortization 33.5 35.5 35.0 R&D expense 13.8 13.7 14.5 Adjusted operating profit 26.6 45.2 38.0 Interest bearing debt 239.7 216.6 210.0 Equity capital 263
Slide 28: Major Subsidiaries
28 Major Subsidiaries － FY2015 Consolidated Results － (Billion Yen) Operating Sales income Subsidiaries and Affiliates Business change from FY2015 FY2014 UBE CHEMICALS (ASIA) PUBLIC CO., LTD Manufacture and sales of caprolactam and polyamide resin 40.0 ↑ Manufacture and sales of caprolactam, ammoniu
Slide 29: Major Items for Capital Expenditure
29 Major Items for Capital Expenditure － FY2016 Consolidated Results － Estimeated Segment Subject Place completion date Reconstruction of Lib-separator Ube, Japan FY2016 facility Osaka Research and Sakai, Japan FY2016 Development Center Extention of Lib-separator Chemicals Sakai, Japan FY2017 facili
Slide 30: Forward-looking statements disclaimer
30 This presentation material contains forward-looking statements concerning UBE’s future plans, strategies, and performance. These forward-looking statements are not historical facts; rather, they represent assumptions and beliefs based on economic, financial, and competitive date currently availab